DOGS (DOGS) 24-hour amplitude reaches 105.1%: Telegram-led 6x reduction in TON fees sparks meme explosion in the ecosystem
Bitget Pulse2026/05/07 07:06Volatility Overview
In the past 24 hours, DOGS has experienced extreme price fluctuations, surging from a low of $0.0000512 to a high of $0.000105, currently at $0.0000938, with an amplitude as high as 105.1%. The 24-hour trading volume has skyrocketed to $213–294 million, significantly higher than usual.
Brief Analysis of the Abnormal Movement
- Telegram founder Pavel Durov announced a six-fold reduction in TON network fees, and positioned Telegram as the largest validator of TON, replacing TON Foundation as the network leader, directly igniting the TON ecosystem.
- TON price surged 35–36%, driving DOGS and other meme coins to jump by 90–140%, with trading volume peaking at $105 million.
- On-chain activity increased, and Aster DEX launched DOGS/USDT perpetual contracts, further amplifying liquidity.
Market Opinions and Outlook
Market sentiment remains highly optimistic; the community views TON’s “super app” upgrade as a long-term catalyst. FOMO drives predictions that DOGS may challenge $0.00012 in the short term, but risks of high volatility and potential pullbacks are emphasized. Analysts note that continued growth of TON ecosystem users may benefit DOGS, but caution against thin order book manipulation.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs
Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.
Fed Officials Turn Hawkish: Daly Says Supply Shocks Should No Longer Be "Wait-and-See," Hammack Suggests More Aggressive Rate Hikes May Be Needed if Inflation Expectations Become Entrenched
San Francisco Fed President Daly stated that the traditional "wait and see" approach to supply-side shocks has been abandoned, noting that businesses in her district are tending to pass rising costs on to consumers and that current inflation risks are "skewed fully to the upside." Cleveland Fed President Hammack said that once the public forms an "inflationary mindset," the difficulty of monetary policy regulation will increase significantly, and the required interest rate hikes will then exceed expectations.
Australian Dollar crumbles as job losses shatter RBA rate hike hopes
Over $10 billion in market value evaporated in four trading days as CoreWeave (CRWV.US) debt risks trigger sell-off, but Deutsche Bank sees it as a buying opportunity
Deutsche Bank believes that the recent sell-off of CoreWeave lacks sufficient company fundamentals to justify it, and the sharp price correction has instead created a buying opportunity for investors.
